

Prevention & Treatment of Hepatitis and Chronic Liver Disease

Cincinnati, OH – December 11, 2021

Conference Location	The Graduate Cincinnati 151 Goodman Drive Cincinnati, OH	Phone: (513) 487-3800 https://www.graduatehotels.com/cincinnati
Parking at the Conference	A parking structure adjacent to the Graduate Cincinnati owned by the University. The self-park rate \$10 per day A limited number of guest rooms are available on Friday evening for \$119 plus taxes	
Driving Directions	The Graduate is located in the heart of the University of Cincinnati campus adjacent to the College of Medicine and just three miles north of downtown. Located just north of Martin Luther King Drive about equidistant between Highways 71 and 75	
Seminar Agenda and Syllabus Information	Registration begins at 7:00am in the Beast Auditorium . Please check signage for any room changes. The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the <i>App</i> will be provided to participants in advance of the seminar. Wi-Fi will be available without charge.	

Pre-Program Activities	Lecture 1 – Viral Hepatitis – the natural history and manifestations of HCV – 60 min Lecture 2 - End Stage Liver Disease: Treatment, Managing Complications and Transplant – 45 min
7:00am	<i>Registration and View Exhibits</i>
7:30 am	Opening Comments and Pre-Test
7:45 am	Hepatitis C: Update on Diagnostics <ul style="list-style-type: none"> • Short recap of key points from Pre-course lecture on viral hepatitis Hepatitis C: Update on Treatment <ul style="list-style-type: none"> • AASLD/IDSA Guidelines and Simplified Guidance Case Studies 1 and 2 –HIV/HCV Co-infection; Infections in persons who inject drugs.
8:50 am	Hepatitis B: Epidemiology, Natural History and Testing <ul style="list-style-type: none"> • The epidemiology of the Hepatitis B infection The growing relationship between HBV and HDV
9:20 am	Delta Hepatitis and Hepatitis E Update <ul style="list-style-type: none"> • Worldwide perspective and promising research studies Real world outcome studies on HDV and HEV
9:50 am	Product Theater #1 Break and View exhibits
10:30 am	Anti-viral Therapies for HBV <ul style="list-style-type: none"> • Early detection and treatment approaches Reactivation of HBV
11:00 am	End Stage Liver Disease: Recap and Clinical Case <ul style="list-style-type: none"> • Recap on staging, workup, and diagnosis of cirrhosis and ESLD Case Study 3 – Cirrhosis and Encephalopathy
11:25 am	Hepatocellular Carcinoma (HCC) <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests Treatment and management options: Ablation, TACE and Surgery

12:00 pm	Luncheon Presentation – Product Theater #2
12:45pm	Dessert and View Exhibits
1:00 pm	Hepatocellular Carcinoma: New Systemic Treatment Options <ul style="list-style-type: none"> • Current FDA-Approved Therapies and those in development Case Study 4– Diagnosis and Treatment of Hepatocellular Carcinoma
1:40 pm	SARS-COV-2 in Liver Disease Effects of COVID on the liver and in cirrhotic patients
2:05pm	Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis <ul style="list-style-type: none"> • Causes and Markers of PBC • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid • Epidemiology of PSC and Ursodiol and Antibiotic Treatments
2:45 pm	Break & View Exhibits
3:00 pm	NAFLD and NASH <ul style="list-style-type: none"> • Epidemiology, Demographics and Diagnosis • Scoring and Management of Fatty Liver Disease Treatment options for thrombocytopenia; including alternatives to platelet transfusion.
3:30 pm	NASH Treatments in Practice and in Development <ul style="list-style-type: none"> • Current therapies and life style changes to reduce NAFLD and NASH • Drugs in clinical development for NASH • NASH Updates from AASLD and EASL
4:15 pm	Closing Comments, Post-test and Wrap-Up Program adjourns at 4:30 pm
Post-program activities	Lecture 3 - Viral Hepatitis Updates: The reemergence of Hep A and Alcoholic Liver Disease – 45 min

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Attendance Policies

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

CME Information

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-22-1205. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

**Your
Seminar
Faculty**



KENNETH E. SHERMAN, MD, PhD

Kenneth E. Sherman received his BS & PhD (Microbiology) from Rutgers University and his MD from George Washington University. Currently, he holds an endowed chair as the Gould Professor of Medicine and serves as the Director of the Division of Digestive Diseases at the University of Cincinnati College of Medicine.

Dr. Sherman's research interests center around viral hepatitis and the pathogenesis, evaluation and treatment of liver disease in those with HIV infection. He is an NIH-funded researcher and holds several patents. Dr. Sherman is the author of over 250 articles, abstracts and book chapters on viral hepatitis and other areas of liver disease. He has held numerous leadership positions in the field.



NAGA CHALASANI, MD

Dr. Chalasani currently serves as David W. Crabb Professor of Medicine and Interim Chair of the Department of Medicine at Indiana University School of Medicine. He previously served as the Director of the Division of Gastroenterology and Hepatology at the same institution from 2007 to 2020.

He completed his medical education in India and subsequently completed Internal Medicine Residency and Gastroenterology & Hepatology subspecialty training at Emory University in Atlanta.

Dr. Chalasani, a practicing hepatologist, is considered an authority in the fields of nonalcoholic fatty liver disease (NAFLD) and drug induced liver injury (DILI), two highly significant public health problems. His research has been continuously funded by the National Institutes of Health since 1999. He published over 300 original papers, 3 Practice Guidelines, 47 book chapters/review articles and more than 500 abstracts..



CARRIE JENNINGS, CNP

Carrie Jennings, CNP is a family nurse practitioner at the University of Cincinnati/UC Health Medical Center in Cincinnati, OH. She has been a member of the Hepatology team within the Division of Digestive Diseases since 2005, where she cares for patients with viral hepatitis, HIV, NASH and other liver diseases. She is involved in numerous clinical research efforts including co-investigator and sub investigator in HCV, HBV, NASH, PSC and PBC clinical trials.

She has co-authored peer reviewed publications and presented at several local, state, and national conferences.

Carrie earned her Master of Science in Nursing from the Ohio State University in 2005, and a Bachelor of Science in Biology in 2002. She is also an adjunct faculty member with the University of Cincinnati College of Nursing MSN program.
